Effects of growth hormone and prolactin on hematopoiesis

Lisbeth A. Welniak, Zhi Gang Tian, Rui Sun, Jonathan R. Keller, Susan Richards, Francis W. Ruscetti, William J Murphy

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


The use of the neuroendocrine hormones growth hormone (GH) and prolactin (PRL) in preclinical models, demonstrating promotion of hematopoietic recovery and immune function, offers promise for several clinical situations. These hormones do not appear to produce the same extent of immune/hematopoietic effects when compared to conventional hematopoietic and immune stimulating cytokines (i.e. G-CSF or interleukin-2). However, their pleiotropic effects and limited toxicity after systemic administration makes them attractive to test in myeloablative situations. More work needs to be performed to understand the mechanism(s) of GH and PRL action, particularly with regard to hematopoietic progenitor cell expansion and differentiation both in normal and pathologic situations.

Original languageEnglish (US)
Pages (from-to)435-445
Number of pages11
JournalLeukemia and Lymphoma
Issue number5-6
StatePublished - 2000
Externally publishedYes


  • Growth hormone
  • Hematopoiesis
  • IGF-I
  • Myelosuppression
  • Prolactin
  • Transplantation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Effects of growth hormone and prolactin on hematopoiesis'. Together they form a unique fingerprint.

Cite this